Updated:
Arcus Ventures
Arcus Ventures is a New York-based private equity firm investing in early-stage and growth-stage companies across the startup-to-expansion lifecycle.
Arcus Ventures
Arcus Ventures is a New York City-based firm founded in 2007. The team consists of professionals with experience in clinical and academic medicine, drug development, hospital management, healthcare industry consulting, and private equity. Arcus Ventures invests in oncology-focused companies with innovative biopharmaceuticals, devices, diagnostics, and services with positive revenue.
General information
Firm type
Venture Capital
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
New York
Corporate office
New York, United States
Frequently asked questions
How does Arcus Ventures source deals without a visible public presence?
Without a published website, LinkedIn activity, or named principals, the firm's sourcing channels are not publicly observable. Private equity managers in this posture typically rely on founder referrals, operator networks, and intermediary relationships that operate below the threshold of public deal announcements. Whether Arcus has developed proprietary origination advantages or acts opportunistically on inbound deal flow is not confirmed by any public source.
Who runs investment decisions at Arcus Ventures?
No investment committee members, managing partners, or principals are named in any public record. The firm's website provides no team biographies, and no regulatory filings identify controlling persons or key decision-makers. Institutional allocators evaluating Arcus would need to conduct direct reference checks and request organizational disclosures, as standard background diligence cannot be performed against the public record.
Is Arcus Ventures structured as a traditional fund or a deal-by-deal vehicle?
The firm has not disclosed its legal structure, fund architecture, or LP composition. Arcus could operate via committed blind-pool funds, special-purpose vehicles raised per transaction, or a permanent capital vehicle — none of which is confirmed in public filings or media coverage. This structural ambiguity is itself a material consideration for any prospective co-investor or LP.
What investment stages does Arcus Ventures target?
The firm's stated strategy covers early-stage startups, expansion rounds, and late-stage growth equity. This continuum suggests Arcus evaluates investments from initial commercial traction through pre-IPO scaling, though the distribution of its actual deployment across these stages is not publicly reported.
Has Arcus Ventures publicly disclosed any portfolio companies?
No. The firm does not list portfolio companies on its website, and no media reports or press releases identify current or exited holdings. Without named investments, external analysts cannot assess sector concentration, check-size range, geographic distribution, or return profile — all standard evaluation points in institutional due diligence.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on venture capital firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: